Characterizing hypertension in activated PI3K delta syndrome: Findings from Epic Cosmos.
- 1Herbert Wertheim College of Medicine, Florida International University , Miami, FL, USA.
- 2Office of Human Research, Memorial Healthcare System , Hollywood, FL, USA.
- 3Division of Immunology, Allergy and Rheumatology, Joe DiMaggio Children's Hospital, Hollywood, FL, USA.
Abstract
APDS is a rare inborn error of immunity with comorbidity patterns that have yet to be characterized at a large scale. Using Epic Cosmos, a de-identified electronic health record database, we conducted a retrospective, cross-sectional analysis of 866 patients identified by structured diagnosis codes (ICD-10: D84.81; SNOMED: 793412000). Findings revealed that hypertension was coded as affecting 28.5% of the cohort, with age-stratified analyses demonstrating higher prevalence among younger APDS patients compared with age-matched non-APDS peers. Among patients aged ≤50 years, hypertension prevalence was 24.05% in the APDS group compared with 10.89% in the age-matched non-APDS population (prevalence ratio 2.21, 95% CI, 1.90-2.57, P < 0.0001). This association remained prominent in a more specific APDS sensitivity cohort in which the base population required an APDS diagnosis, alongside an allergy and immunology encounter. The findings of this paper provide large-scale characterization of APDS and identify hypertension, particularly among younger APDS patients, as a potentially underrecognized comorbidity that warrants further investigation.
Related
- Heterozygous Mutations in MAP3K7 , Encoding TGF-β-Activated Kinase 1, Cause Cardiospondylocarpofacial Syndrome
- Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety
- Effectiveness of leniolisib in reducing infections among patients with activated phosphoinositide 3-kinase δ syndrome (APDS).
- Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study
- Clinical Manifestations and Genetic Findings in Three Patients with Chediak-Higashi Syndrome: Highlighting the Splice Site Variants
BibTeX
@article{santiago2026characterizing,
title = {{Characterizing hypertension in activated PI3K delta syndrome: Findings from Epic Cosmos.}},
author = {Brianna Santiago and Jennifer Keelin and Xiaoqi Sun and Christopher Chang},
journal = {Journal of human immunity},
year = {2026},
month = oct,
doi = {10.70962/jhi.20250263},
url = {https://europepmc.org/article/MED/42929758},
note = {CC BY},
}
RIS
TY - JOUR
TI - Characterizing hypertension in activated PI3K delta syndrome: Findings from Epic Cosmos.
AU - Brianna Santiago
AU - Jennifer Keelin
AU - Xiaoqi Sun
AU - Christopher Chang
PY - 2026
DA - 2026/10/26
JO - Journal of human immunity
DO - 10.70962/jhi.20250263
UR - https://europepmc.org/article/MED/42929758
AB - APDS is a rare inborn error of immunity with comorbidity patterns that have yet to be characterized at a large scale. Using Epic Cosmos, a de-identified electronic health record database, we conducted a retrospective, cross-sectional analysis of 866 patients identified by structured diagnosis codes (ICD-10: D84.81; SNOMED: 793412000). Findings revealed that hypertension was coded as affecting 28.5% of the cohort, with age-stratified analyses demonstrating higher prevalence among younger APDS patients compared with age-matched non-APDS peers. Among patients aged ≤50 years, hypertension prevalence was 24.05% in the APDS group compared with 10.89% in the age-matched non-APDS population (prevalence ratio 2.21, 95% CI, 1.90-2.57, P < 0.0001). This association remained prominent in a more specific APDS sensitivity cohort in which the base population required an APDS diagnosis, alongside an allergy and immunology encounter. The findings of this paper provide large-scale characterization of APDS and identify hypertension, particularly among younger APDS patients, as a potentially underrecognized comorbidity that warrants further investigation.
SN - 3065-8993
ER -